Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Tucatinib Called Game-Changer in HER2-Positive Metastatic Breast Cancer

Publish date:: December 12, 2019

Key clinical point: Tucatinib is being hailed as a major therapeutic advance for women with heavily pretreated HER2-positive metastatic breast cancer.

Major finding: The 2-year estimated overall survival was 45% in patients on tucatinib and 27% with placebo.

Study details: This pivotal double-blind trial included 612 women with heavily pretreated HER2-positive metastatic breast cancer who were randomized two-to-one to tucatinib or placebo in combination with trastuzumab and capecitabine.

Disclosures: The presenter reported receiving institutional research support from and serving as a consultant to Seattle Genetics, sponsor of the HER2CLIMB trial.

Citation:

Murthy RK. SABCS 2019. Abstract GS1-01.

This Week's Must Reads

Consider potential cognitive complications prior to androgen deprivation therapy,

Diabetes raises risk of prostate cancer mortality in obese men,

Salivation inhibition fails to reduce radioiodine toxicity in prostate cancer,

Highest positive surgical margin predicts poor survival after prostatectomy,

Young minority men are underinformed about prostate cancer screening,

Must Reads in Breast Cancer

Ten-Year Results Support Partial Breast Irradiation,

Tucatinib Called Game-Changer in HER2-Positive Metastatic Breast Cancer,

Bilateral Mastectomy Reduces Second Breast Cancer Risk, but not Death,

Single-Fraction Radiation Misses Mark for Spinal Compression Relief,

Study Detects Lower CV Risk in Breast Cancer Survivors,